These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 39354416)
1. Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis. Abraham Y; Assefa DG; Hailemariam T; Gebrie D; Debela DT; Geleta ST; Tesfaye D; Joseph M; Manyazewal T BMC Infect Dis; 2024 Oct; 24(1):1087. PubMed ID: 39354416 [TBL] [Abstract][Full Text] [Related]
2. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240 [TBL] [Abstract][Full Text] [Related]
3. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH; Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617 [TBL] [Abstract][Full Text] [Related]
4. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria. Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492 [TBL] [Abstract][Full Text] [Related]
5. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Sharma SK; Sharma A; Kadhiravan T; Tharyan P Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580 [TBL] [Abstract][Full Text] [Related]
6. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771 [TBL] [Abstract][Full Text] [Related]
7. Linezolid for drug-resistant pulmonary tuberculosis. Singh B; Cocker D; Ryan H; Sloan DJ Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466 [TBL] [Abstract][Full Text] [Related]
8. Bedaquiline versus injectable containing regimens for rifampicin-resistant and multidrug-resistant tuberculosis in a reference center in Brazil - a real-world evidence study using a retrospective design. Santos AP; Benace CJ; de Medeiros Leung JA; Kritski AL; de Queiroz Mello FC BMC Infect Dis; 2024 Oct; 24(1):1112. PubMed ID: 39375590 [TBL] [Abstract][Full Text] [Related]
9. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study. Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187 [TBL] [Abstract][Full Text] [Related]
10. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis. Maier C; Chesov D; Schaub D; Kalsdorf B; Andres S; Friesen I; Reimann M; Lange C Clin Microbiol Infect; 2023 Jun; 29(6):751-757. PubMed ID: 36842637 [TBL] [Abstract][Full Text] [Related]
11. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China. Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829 [TBL] [Abstract][Full Text] [Related]
13. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Sharma SK; Sharma A; Kadhiravan T; Tharyan P Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581 [TBL] [Abstract][Full Text] [Related]
14. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
15. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials. Wang M; Guan X; Chi Y; Robinson N; Liu JP Tuberculosis (Edinb); 2015 Jul; 95(4):364-72. PubMed ID: 25861717 [TBL] [Abstract][Full Text] [Related]
16. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis. Hasan T; Medcalf E; Nyang'wa BT; Egizi E; Berry C; Dodd M; Foraida S; Gegia M; Li M; Mirzayev F; Morgan H; Motta I; Nguyen L; Schumacher S; Schlub T; Fox G Clin Infect Dis; 2024 Mar; 78(3):730-741. PubMed ID: 37874021 [TBL] [Abstract][Full Text] [Related]
17. Six-month therapy for abdominal tuberculosis. Jullien S; Jain S; Ryan H; Ahuja V Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499 [TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Kibret KT; Moges Y; Memiah P; Biadgilign S Infect Dis Poverty; 2017 Jan; 6(1):7. PubMed ID: 28093078 [TBL] [Abstract][Full Text] [Related]
19. Drug-resistance characteristics, genetic diversity, and transmission dynamics of multidrug-resistant or rifampicin-resistant Mycobacterium tuberculosis from 2019 to 2021 in Sichuan, China. Gao W; Wang W; Li J; Gao Y; Zhang S; Lei H; He L; Li T; He J Antimicrob Resist Infect Control; 2024 Oct; 13(1):125. PubMed ID: 39396971 [TBL] [Abstract][Full Text] [Related]
20. Update of drug-resistant tuberculosis treatment guidelines: A turning point. Vanino E; Granozzi B; Akkerman OW; Munoz-Torrico M; Palmieri F; Seaworth B; Tiberi S; Tadolini M Int J Infect Dis; 2023 May; 130 Suppl 1():S12-S15. PubMed ID: 36918080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]